Community Pharmacy England has today released a national report highlighting how pharmacy owners across England are dipping into personal savings to support their businesses, effectively subsidising the provision of NHS services. The Pharmacy Pressures Survey 2025: Funding and Profitability Report sets out once again the desperate financial position community pharmacies are in as a result of
Read moreThe Department of Health and Social Care (DHSC) has issued a medicine supply notification for the following product: Repaglinide 500microgram,1mg and 2mg tablets MSN/2025/050 Tier 2 – medium impact Date of issue: 26/08/2025 Repaglinide 500microgram and 1mg tablets will be out of stock from late August until early December 2025 Repaglinide 2mg tablets are in
Read moreMHRA Class 4 Medicines Notification: Various Products (Ipca Laboratories UK Limited) Date issued: 26 August 2025 Ipca Laboratories UK Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in the products listed in this notification do not contain all the required safety information. DMRC reference number: DMRC-35766519 Marketing Authorisation Holder: Ipca Laboratories UK
Read moreFollowing representations made by Community Pharmacy England on behalf of community pharmacy owners, the Department of Health and Social Care (DHSC) has redetermined the June and July 2025 reimbursement prices for the following products, to reflect an increase in their NHS list prices. To avoid pharmacy owners dispensing these products at a loss, DHSC has agreed
Read moreAs part of our Funding & Reimbursement Shorts series, Community Pharmacy England’s in-house Drug Tariff and funding experts have created a new video on the end of month submission process. For the end-of-month submission, pharmacy teams are required to declare the month’s dispensing activity by completing the FP34C form on the Manage Your Service (MYS) portal.
Read moreThe Department of Health and Social Care (DHSC) has today (22/08/2025) confirmed the following list of price concessions for August 2025: Drug Pack size Price concession Clarithromycin 125mg/5ml oral suspension 70 £5.54 Esomeprazole 20mg gastro-resistant capsules 28 £4.23 Esomeprazole 40mg gastro-resistant capsules 28 £2.56 Ferrous gluconate 300mg tablets 28 £2.05 Ivabradine 7.5mg tablets 56 £3.17 Latanoprost
Read moreMHRA Class 4 Medicines Defect Notification: Fexofenadine Hydrochloride 120mg film-coated tablets (Chanelle Medical Unlimited Company) Drug alert number: EL(25)A/41 Date issued: 21 August 2025 Chanelle Medical Unlimited Company has informed the MHRA of an error with the European Article Number (EAN) / Global Trade Item Number (GTIN) barcode on certain batches of Fexofenadine Hydrochloride 120mg film-coated
Read moreThe Department of Health and Social Care (DHSC) has today (19/08/2025) confirmed the following initial list of price concessions for August 2025: Drug Pack size Price concession Alfuzosin 2.5mg tablets 60 £7.22 Clarithromycin 250mg/5ml oral suspension 70 £10.52 Cyclizine 50mg/1ml solution for injection ampoules 5 £4.01 Dutasteride 500microgram capsules 30 £2.88 Ibuprofen 600mg tablets 84 £9.38
Read moreMHRA Class 4 Medicines Defect Notification: Levetiracetam 100mg/ml oral solution (Accord Healthcare Limited) Date issued: 14 August 2025 Drug Alert Number: EL(25)A/40 Accord Healthcare Limited, UK has informed the MHRA that the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SPC) do not contain all the required safety information. DMRC reference number: DMRC-35838218 Marketing Authorisation
Read moreDapagliflozin 5mg and 10mg tablets will be moving from Category C to Category M in the September 2025 Drug Tariff. This comes after several manufacturers launched generic versions of Dapagliflozin tablets following the recent ruling by the UK Court of Appeal to invalidate AstraZeneca’s patent for the brand Forxiga®. Currently, all branded and generically written prescriptions
Read more
